

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A recombinant papilloma virus like particle (VLP) for introduction of a peptide into cells, comprising a major capsid protein L1 of human papilloma virus (HPV-L1 protein) wherein the major capsid protein L1 of human papilloma virus has been intentionally modified by site-specific substitution of specific amino acids to abolish major type specific epitopes causing production of neutralising antibodies.

2. (Currently Amended) The recombinant papilloma virus like particle (VLP) according to claim 1, wherein the L1 protein is homologous to the L1 protein of derived from human papilloma virus 16.

3. (Currently Amended) The recombinant papilloma virus like particle (VLP) according to claim 2, wherein the L1 protein of HPV 16 (SEQ ID NO:1) has been modified by substitution of two or more of amino acids selected from the group consisting of Asn56, Asp138, Asn270, Asn285, Ile348, Ser349, Thr350, Ser351, Glu352, TThr353.

4. (Currently Amended) The recombinant papilloma virus like particle (VLP) according to claim 1, wherein the peptide is genetically fused to the modified

L1 protein.

5. (Currently Amended) A composition consisting of comprising the recombinant papilloma virus like particle (VLP) of claim 1, and one or more pharmaceutically acceptable carriers, adjuvants or diluents.